These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9460702)

  • 1. Inhibitors of catecholamine metabolizing enzymes cause changes in S-adenosylmethionine and S-adenosylhomocysteine in the rat brain.
    Yassin MS; Cheng H; Ekblom J; Oreland L
    Neurochem Int; 1998 Jan; 32(1):53-9. PubMed ID: 9460702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase.
    Zhao WQ; Latinwo L; Liu XX; Lee ES; Lamango N; Charlton CG
    Exp Neurol; 2001 Sep; 171(1):127-38. PubMed ID: 11520127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats.
    Miller JW; Shukitt-Hale B; Villalobos-Molina R; Nadeau MR; Selhub J; Joseph JA
    Clin Neuropharmacol; 1997 Feb; 20(1):55-66. PubMed ID: 9037574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain ATP:L-methionine S-adenosyltransferase (MAT), S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH): regional distribution and age-related changes.
    Trolin CG; Löfberg C; Trolin G; Oreland L
    Eur Neuropsychopharmacol; 1994 Dec; 4(4):469-77. PubMed ID: 7894257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
    Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
    J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.
    Vieira-Coelho MA; Soares-da-Silva P
    Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats.
    Tuomainen P; Törnwall M; Männistö PT
    Pharmacol Toxicol; 1996 Jun; 78(6):392-6. PubMed ID: 8829199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase.
    Borges N; Vieira-Coelho MA; Parada A; Soares-da-Silva P
    J Pharmacol Exp Ther; 1997 Aug; 282(2):812-7. PubMed ID: 9262345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contribution by monoamine oxidase and catechol-O-methyltransferase to the total-body and pulmonary plasma clearance of catecholamines.
    Friedgen B; Wölfel R; Graefe KH
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Jan; 353(2):193-9. PubMed ID: 8717160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the role of O-methylation in the metabolism of S-adenosylmethionine in rat brain.
    Waldmeier PC; Feldtrauer JJ
    Biochem Pharmacol; 1987 Sep; 36(17):2855-61. PubMed ID: 3632711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
    Müller T; Kuhn W
    Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
    Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
    Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of vitamin B6 deficiency on the synthesis and accumulation of S-adenosylhomocysteine and S-adenosylmethionine in rat tissues.
    Nguyen TT; Hayakawa T; Tsuge H
    J Nutr Sci Vitaminol (Tokyo); 2001 Jun; 47(3):188-94. PubMed ID: 11575573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
    Li YH; Wirth T; Huotari M; Laitinen K; MacDonald E; Männistö PT
    Eur J Pharmacol; 1998 Sep; 356(2-3):127-37. PubMed ID: 9774242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone.
    Vieira-Coelho MA; Soares-da-Silva P
    Br J Pharmacol; 1996 Feb; 117(3):516-520. PubMed ID: 8821542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease.
    Cheng H; Gomes-Trolin C; Aquilonius SM; Steinberg A; Löfberg C; Ekblom J; Oreland L
    Exp Neurol; 1997 Jun; 145(2 Pt 1):580-5. PubMed ID: 9217094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats.
    Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I
    J Pharm Pharmacol; 1995 Jun; 47(6):539-42. PubMed ID: 7674141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opposite effects of tolcapone on amphetamine-disrupted startle gating in low vs. high COMT-expressing rat strains.
    Swerdlow NR; Hines SR; Herrera SD; Weber M; Breier MR
    Pharmacol Biochem Behav; 2013 May; 106():128-31. PubMed ID: 23567203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of dopamine-metabolizing enzymes in the regulation of renal sodium excretion in the rat.
    Odlind C; Reenilä I; Männistö PT; Ekblom J; Hansell P
    Pflugers Arch; 2001 Jul; 442(4):505-10. PubMed ID: 11510881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.